Now showing items 21-22 of 22

    • Targeting DNA damage response in oesophagogastric cancers 

      Starling N; Cartwright, E; Starling, N (Institute of Cancer Research (University Of London), 2023-05-30)
      A subset of patients with oesphophagogastric (OG) adenocarcinomas are characterised by homologous recombination repair deficiency (HRD), providing the rationale for poly (ADP-ribose) polymerase inhibitor (PARPi) therapy ...
    • Utilising novel therapies in the treatment of gastrointestinal cancers 

      Starling N; Turkes, F; Starling, N (Institute of Cancer Research (University Of London), 2023-05-04)
      Background: Gastrointestinal (GI) malignancies are common and frequently lethal diseases. For most, treatment options revolve around chemotherapy where efficacy beyond second line is negligible, and toxicity is high. Novel ...